DrugBiological
Lerodalcibep clinical trials
Also written LIB003 and HST101.
- studies test it
- 12
- open now
- 5
- in phase 3
- 11
- first study started
- 2019
Keep track of what changes. Save the lerodalcibep studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
11 studies that test it; most in 2021 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 3
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
LIB Therapeutics LLC (10) · Hasten Biopharmaceutical Co., Ltd. (2)
Studies
Open first, then newest update. How each study uses lerodalcibep is read from its arms, and is right about nine times in ten.
Testing it · 12
- Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial HypercholesterolemiaNot yet recruitingPhase 3LIB Therapeutics LLCNCT07775339Written as Lerodalcibep
- Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHEnrolling by invitationPhase 3LIB Therapeutics LLCNCT07102511Written as lerodalcibep 300 mg Monthly SC
- A Study on Evaluating the Safety of HST101 in Healthy Chinese ParticipantsEnrolling by invitationPhase 1Hasten Biopharmaceutical Co., Ltd.NCT06504043Written as HST101
- A Study on Efficacy and Safety of HST101 in Chinese Patients with HypercholesterolemiaRecruitingPhase 3Hasten Biopharmaceutical Co., Ltd.NCT06568471Written as Lerodalcibep
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionEnrolling by invitationPhase 3LIB Therapeutics LLCNCT04798430Written as lerodalcibep
- Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C ReductionCompletedPhase 3LIB Therapeutics LLCNCT04797104Written as lerodalcibep
- Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD PatientsCompletedPhase 3LIB Therapeutics LLCNCT05004675Written as lerodalcibep
- Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C ReductionActive, not recruitingPhase 3LIB Therapeutics LLCNCT04797247Written as lerodalcibep
- Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C ReductionActive, not recruitingPhase 3LIB Therapeutics LLCNCT04806893Written as lerodalcibep
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD PatientsCompletedPhase 3LIB Therapeutics LLCNCT04790513Written as lerodalcibep
- Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFHCompletedPhase 3LIB Therapeutics LLCNCT04034485Written as lerodalcibep
- Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug ProductCompletedPhase 3LIB Therapeutics LLCNCT05234775Written as lerodalcibep
Codes
What other systems call lerodalcibep · ClinicalTrials.gg INT002182
- MeSH (NLM) C000731963lerodalcibepOne source NLM
- UNII (FDA) 1PHP3QG5PZLERODALCIBEPConfirmed FDA, NLM
- NCI Thesaurus C175808LerodalcibepOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731963 | lerodalcibep | One source NLM |
| UNII (FDA) | 1PHP3QG5PZ | LERODALCIBEP | Confirmed FDA, NLM |
| NCI Thesaurus | C175808 | Lerodalcibep | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.